Categories: News

Update on full-year outlook for 2022

Company announcement no. 26 – 22
6 December 2022

Update on full-year outlook for 2022

Based on the financial performance during the first ten months of 2022, preliminary financial results for November 2022, and financial expectations for December 2022, NTG Nordic Transport Group A/S (“NTG”) adjusts its full-year outlook for 2022 as follows:

  • Revenue around DKK 10,200 million (previously DKK 9,700 – 10,200 million)
  • Adj. EBIT around DKK 750 million (previously DKK 700 – 750 million)

The full-year outlook for 2022 is adjusted based on indications of a stabilisation in certain markets during November and December of the year.

Additional information

For additional information, please contact:

Investor relations:
Christian D. Jakobsen, Group CFO                                    
+45 42 12 80 99
ir@ntg.com
Press:
Mathias Jensen-Vinstrup, Executive Vice President
+45 42 12 80 90
press@ntg.com

Attachment

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

17 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

17 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

17 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

17 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

17 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

17 hours ago